drugset / Trial / NCT03861338
An Open-Label Pilot Study of Sublocade as Treatment for Opiate Use Disorder
NaSingle-groupOpen-labelTreatment
Summary
The proposed study is a 12-week, open-label pilot study of sublocade (extended-release burprenorphine, BXR) as treatment for opiate use disorder (OUD) testing positive for Highly Potent Synthetic Opioids (HPSO). The investigators plan to enroll 10 participants into the study.
Timeline
- Start
- 2019-03-01
- Primary completion
- 2020-02-28
- Completion
- 2020-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Buprenorphine | Other / unclassified | 100 mg | Subcutaneous |
| Subject | Buprenorphine | Other / unclassified | 300 mg | Subcutaneous |